Skip to main content
Oxurion NV logo

Oxurion NV — Investor Relations & Filings

Ticker · OXUR ISIN · BE0974487192 LEI · 549300VWY8KVDFKLDM59 BR Professional, scientific and technical activities
Open in API
Filings indexed 1,031 across all filing types
Latest filing 2022-11-25 Declaration of Voting R…
Country BE Belgium
Listing BR OXUR

About Oxurion NV

https://oxurion.com/

Oxurion NV is a company focused on acquiring majority stakes in European pharmaceutical subcontractors. Its strategy is to build an integrated group of contract service providers to support healthcare stakeholders. A key asset in its portfolio is a majority stake in Axiodis CRO, a contract research organization specializing in biometrics. This investment-based business model represents a strategic pivot from the company's former focus on the internal research and development of therapies for retinal diseases such as Geographic Atrophy (GA) and Age-related Macular Degeneration (AMD).

Recent filings

Filing Released Lang Actions
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA" and explicitly states that it is announcing the updated total number of shares issued and the resulting denominator for shareholding calculations, as required by Belgian law (article 15 of the Belgian Act of May 2, 2007). This type of announcement, which details changes in the total number of voting rights (the denominator) following capital events like bond conversions, is a specific regulatory disclosure related to share capital structure and ownership thresholds. While it involves capital changes, its primary focus is the resulting voting rights count. This fits best under the category related to changes in share ownership/capital structure reporting, but specifically, the core content is about the total voting rights count, which is often a required disclosure when major shareholding thresholds are crossed or capital changes occur. Given the options, this is a specific regulatory disclosure concerning the capital structure and voting rights count. It is not a general Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). It is not a Director's Dealing (DIRS) or a general Major Shareholding Notification (MRQ), although it impacts the denominator used for MRQ calculations. The closest fit among the provided codes that covers specific regulatory disclosures about share capital and voting rights is 'Share Issue/Capital Change' (SHA) or potentially 'Major Shareholding Notification' (MRQ) if interpreted broadly, but since it explicitly details the new total number of voting rights (the denominator), it is a direct consequence of a capital change event (bond conversion). However, the document's structure and content—providing the updated denominator as mandated by law—is a very specific type of regulatory filing. Since the document is a direct announcement of the updated denominator following capital increases, it strongly relates to capital structure changes. I will classify it as 'Share Issue/Capital Change' (SHA) as the underlying event is the issuance of new shares via conversion, which directly changes the capital structure and voting rights count. Alternatively, since it is a mandatory disclosure of the denominator, it could be seen as a specific regulatory filing (RNS), but SHA is more precise for the underlying event. Revisiting the definitions: SHA is 'Announcement regarding new share issues, stock splits, or other capital changes.' This document details the result of capital changes (conversions) and the resulting total shares/voting rights. This is the most appropriate fit.
2022-11-25 English
OXUR PR_Voting rights (NED)_20221125.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend op NEGMA Conversie-Notificatie' and explicitly states that it is publishing updated information regarding the total number of voting rights (the denominator) following capital increases due to convertible bond conversions. It cites Article 15 of the Belgian law on the disclosure of major shareholdings. This type of mandatory disclosure, focusing specifically on the total number of shares outstanding used as a denominator for ownership calculations, is a regulatory filing related to share capital changes and ownership transparency. While it involves capital changes (CAP) and major shareholding changes (MRQ), the primary function described is the official notification of the total voting rights count, which aligns best with a specific regulatory disclosure requirement. Given the options, this is a specific regulatory announcement concerning share capital structure and voting rights, which is often categorized under general regulatory filings or specific capital/share announcements. Since it details the resulting total number of shares after a financing event (conversion of bonds), and is a formal public disclosure ('PERSBERICHT' / 'Gereglementeerde informatie'), it fits the criteria for a Capital/Financing Update (CAP) or a general Regulatory Filing (RNS). However, the core content is the calculation and announcement of the new total number of shares/voting rights, which is a direct consequence of a financing/capital event. In many jurisdictions, this specific type of disclosure is mandated alongside or immediately following capital changes. Given the strong focus on the resulting share count after financing conversions, 'CAP' (Capital/Financing Update) is a strong candidate, but 'RNS' (Regulatory Filings) is the most appropriate general category for mandatory, non-periodic disclosures like this specific 'Noemer' notification, especially when a more specific code like 'SHA' (Share Issue/Capital Change) might imply the *announcement* of the issue rather than the *post-event* tally required by law. Since the document is a formal press release announcing the regulatory denominator update following financing, RNS is the safest and most encompassing classification for mandatory, non-periodic regulatory updates that don't fit perfectly elsewhere, although it is closely related to CAP/SHA. I will classify it as RNS as it is a specific regulatory notification ('Gereglementeerde informatie - Noemer').
2022-11-25 Dutch
20221118-Oxurion_Update N (18 11 22)_Art. 15 UK.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is explicitly titled "Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA" and details a capital increase resulting from the conversion of convertible bonds. It concludes by stating the new total number of outstanding ordinary shares, which serves as the denominator for calculating shareholding percentages, as required by Belgian law (Article 15). This specific disclosure relates to changes in the total number of shares/voting rights, which is a form of capital structure update or a mandatory regulatory disclosure concerning share capital. While it involves capital changes (CAP), the primary focus and explicit regulatory context provided ('Denominator' disclosure) strongly align with announcements related to share structure and voting rights calculation. Among the provided codes, 'SHA' (Share Issue/Capital Change) is the most appropriate fit for a document detailing the issuance of new shares and the resulting change in the total share count used as a denominator. It is not a general earnings release (ER), a full annual report (10-K), or a general capital raising announcement (CAP), but a specific notification about the resulting share count.
2022-11-18 English
20221118-Oxurion_Update N (18 11 22)_Art. 15 NL.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is titled 'Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend op NEGMA Conversie-Notificatie' and explicitly states that it is publishing updated information regarding the total number of voting rights (the denominator) following a capital increase due to convertible bond conversion. It details the change in the total number of outstanding shares (123,781,647) and lists various outstanding rights and convertible bonds. This type of mandatory disclosure, focusing on the total number of shares for calculating ownership percentages, is a specific regulatory filing related to capital structure changes and major shareholdings, often triggered by financing events. While it involves capital changes (CAP) and major shareholding notifications (MRQ), the core purpose is the official announcement of the new share count denominator as required by securities law (mentioned as Article 15 of the Belgian law). Since the document is a formal press release announcing a change in the share count denominator following a financing event, it most closely aligns with a notification about capital structure changes or a major shareholding threshold crossing, but the specific focus on the 'Noemer' (denominator) calculation following a capital event strongly suggests a notification related to share capital changes or major holdings. Given the options, 'Share Issue/Capital Change' (SHA) covers the underlying event (issuance of new shares via conversion), and 'Major Shareholding Notification' (MRQ) covers the consequence (change in denominator). However, the document is a formal regulatory disclosure about the resulting share count. In many jurisdictions, the announcement of the total number of voting rights (the denominator) is a specific requirement tied to capital changes or major ownership changes. Since the text explicitly details the issuance of new shares (14,705,882 new ordinary shares) and the resulting total share count, SHA (Share Issue/Capital Change) is the most appropriate primary classification for the event described, even though it is presented as a 'Noemer' notification.
2022-11-18 Dutch
OXUR Corporate Update (EN) 2022.1118 FINAL.pdf
Regulatory Filings Classification · 95% confidence The document is explicitly titled "PRESS RELEASE" and announces an "Interim Analysis for KALAHARI Trial" with expected dates for the analysis and full top-line data. This is a typical announcement regarding clinical trial progress, which is a form of corporate update related to ongoing research and development. It is not a full Annual Report (10-K), a comprehensive Interim Report (IR), a formal Earnings Release (ER), or a transcript (CT). Since it is a specific announcement about clinical trial progress and timelines, it doesn't fit perfectly into the standard financial filing codes like 10-K, IR, or ER. However, it is a specific corporate update that is not covered by the other specialized codes (like DIRS, DIV, MANG, etc.). Given the options, this type of announcement, which is a press release detailing operational/clinical milestones, often falls under general Regulatory Filings (RNS) if a more specific category like 'Clinical Trial Update' is unavailable, or sometimes it is grouped with Earnings Releases if it contains key performance indicators, but here it is purely clinical progress. Since RNS is the general regulatory announcement fallback, and this is a formal announcement of a clinical milestone, RNS is the most appropriate general classification among the choices provided for a non-standard, time-sensitive corporate update.
2022-11-18 English
OXUR Corporate Update (NED) 2022.1118 FINAL.pdf
Regulatory Filings Classification · 95% confidence The document is explicitly titled "PERSBERICHT" (Press Release) and contains regulated information. It announces an update regarding the timeline for the interim analysis and full top-line data for the KALAHARI clinical trial (THR-149). This type of announcement, which provides key operational and clinical updates outside of a full financial report (like 10-K or IR), typically falls under an Earnings Release (ER) if it relates to periodic results, or a general Regulatory Filing (RNS) if it's operational news. Since it is a specific announcement about clinical trial progress and timelines, and not a full financial statement, it is best classified as an Earnings Release (ER) as these often include operational milestones alongside financial highlights, or RNS if it's purely operational. Given the context of clinical trial updates being common in ERs, and the document being a press release announcing specific operational news, ER is a strong candidate. However, since it is not explicitly reporting quarterly/periodical financial results (it's a clinical update), and it is a general regulatory announcement, RNS (Regulatory Filings) serves as the most appropriate general category for non-standard, material operational news releases that don't fit other specific codes like DIV, CAP, or MANG. Given the options, and that it is a press release announcing operational/clinical progress, RNS is the safest general regulatory classification, although ER is plausible if this was tied to a quarterly update cycle. I will lean towards RNS as the most general fit for a non-financial, material press release.
2022-11-18 Dutch

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.